In this episode, we explore Human Adenovirus (HAdV), a double-stranded DNA virus that typically causes mild respiratory or gastrointestinal illnesses in healthy individuals but poses a life-threatening risk to immunocompromised patients, particularly haematopoietic stem cell (HSCT) and solid organ transplant recipients. We discuss how severe manifestations—such as pneumonia, hepatitis, and haemorrhagic cystitis—can lead to mortality rates approaching 80% in disseminated cases, especially among children and those with severe T-cell depletion.

We examine the diagnostic landscape, highlighting how PCR screening of blood and stool is crucial for early detection in high-risk paediatric patients, as viral expansion in the gut often precedes systemic spread. Finally, we cover the difficult treatment terrain: while reducing immunosuppression remains the primary strategy, clinicians often rely on the nephrotoxic antiviral cidofovir. We also analyse the promising but turbulent development of newer therapies, including the lipid-conjugate brincidofovir and virus-specific T-cell (VST) immunotherapies, noting the recent discontinuation of Phase 3 trials for the VST posoleucel due to futility.

In this episode, we explore the diagnosis and management of anal fistulas and anorectal malformations (ARMs), distinguishing between acquired conditions and congenital defects like H-type fistulas and the VACTERL association. We break down the trade-offs in surgical interventions, comparing the recurrence rates and continence risks of sphincter-sparing techniques (like LIFT) versus traditional fistulotomies and cutting setons. Finally, we discuss the role of international registries like ARM-Net in tracking long-term outcomes and improving quality of life for patients transitioning from pediatric to adult care.

In this episode, we examine Biliary Atresia (BA), a rare and severe neonatal liver disorder characterized by the progressive obstruction of bile ducts. We discuss the critical importance of early screening using stool colour cards and the serum biomarker MMP-7, alongside the 2025 clinical practice guidelines for diagnosis and management. We explore the complex aetiology of the disease, including the "two-hit" hypothesis involving viral triggers and environmental toxins like biliatresone, as well as recent genetic susceptibility findings. Finally, we review treatment outcomes, highlighting that while the Kasai portoenterostomy remains the first-line surgery, emerging therapies such as ileal bile acid transporter inhibitors and mesenchymal stem cells offer new hope for delaying liver transplantation.

In this episode, we explore hypospadias, a common congenital condition affecting approximately 1 in 200 to 300 newborn males where the urethral opening is displaced. We unpack the complex etiology involving genetic mutations in genes like MAMLD1 and AR, alongside environmental factors. We also discuss surgical standards, typically recommended between 6 and 18 months of age using techniques like TIP or two-stage repairs for severe posterior forms, and review long-term outcomes, highlighting that while most adults report good sexual function, lifelong follow-up is critical for managing potential complications and fertility issues.

In this episode, we explore the 2024 landscape of Cystic Fibrosis, where widespread use of CFTR modulators like Trikafta has pushed median predicted survival to nearly 70 years and drastically reduced lung transplants. We discuss the latest clinical advancements—including the "next-generation" Vanzacaftor triple therapy—and the urgent race to develop gene editing and mRNA solutions for the 10% of patients currently ineligible for modulators. Finally, we examine the shifting challenges of living longer with CF, from managing mental health and financial burdens to navigating reproductive choices and aging.

In this episode, we explore Brugada Syndrome, a rare genetic arrhythmia characterized by specific "coved" ST-segment elevations on an electrocardiogram (ECG) that predisposes individuals to ventricular fibrillation and sudden cardiac death. We discuss its epidemiology, noting a distinct prevalence in men and individuals of Southeast Asian descent, as well as its tendency to cause cardiac events during sleep or rest. We also examine critical triggers like fever and specific medications, the role of the SCN5A gene, and current management strategies, including Implantable Cardioverter Defibrillators (ICDs), quinidine, and epicardial catheter ablation.

In this episode, we explore Vulvar Intraepithelial Neoplasia (VIN), a precancerous condition now classified primarily into HPV-associated High-grade Squamous Intraepithelial Lesions (HSIL) and the more aggressive, HPV-independent differentiated VIN (dVIN). We examine the shift from surgical excision as the sole standard of care to medical interventions like topical imiquimod and cidofovir, which offer effective alternatives that preserve vulvar anatomy and function. Finally, we discuss the critical importance of long-term surveillance, as recurrence remains common regardless of the treatment modality used.

In this episode, we explore the diagnosis and management of Limbal Stem Cell Deficiency (LSCD), a blinding ocular surface disease caused by burns, contact lens wear, and genetic disorders. We discuss established surgical treatments like SLET and CLAU, alongside cutting-edge advances in 3D bioprinting and induced pluripotent stem cell (iPSC) therapies for corneal regeneration.

In this episode, we explore Congenital Sucrase-Isomaltase Deficiency (CSID), a genetic disorder impairing the digestion of sugar and starch that is frequently misdiagnosed as Irritable Bowel Syndrome (IBS). We discuss the wide spectrum of symptoms, ranging from chronic diarrhea to bloating, and how variants in the SI gene contribute to the condition. Finally, we review diagnostic tools and management strategies, including specific dietary modifications and enzyme replacement therapy.

In this episode, we explore the latest developments in Marfan syndrome, a genetic condition caused by mutations in the FBN1 gene that affects connective tissue in the heart, eyes and skeleton. We discuss the $1.44 million in 2025 research grants awarded by The Marfan Foundation, which support cutting-edge projects like using digital twin technology to predict aortic risk and identifying new biomarkers for aneurysm severity.

We also review critical treatment updates, including:

• Medical Therapy: Evidence from the AIMS trial showing that the angiotensin receptor blocker irbesartan significantly reduces the rate of aortic root dilatation compared to placebo.
• Surgical Options: A comparison of valve-sparing aortic root replacement (David procedure) versus composite valve grafts, noting that whilst valve-sparing approaches offer improved long-term survival and avoid lifelong anticoagulation, they carry a higher risk of future valvular deterioration.
• Differential Diagnosis: The importance of distinguishing Marfan syndrome from Loeys-Dietz syndrome, which presents with more aggressive arterial aneurysms and widespread vascular tortuosity.